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Background
The graft-versus-leukemia effect is able to induce clinical responses in patients with chron-
ic lymphocytic leukemia treated with a reduced intensity conditioning regimen, followed
by allogeneic stem cell transplantation. We investigated whether molecular remissions
could be attained after reduced intensity conditioning and allogeneic stem cell transplan-
tation in patients with relapsed chronic lymphocytic leukemia and whether the assess-
ment of minimal residual disease might be used to predict the clinical outcome.
Design and Methods
Minimal residual disease was monitored by polymerase chain reaction using the
immunoglobulin heavy-chain gene rearrangement as a molecular marker in 29 relapsed
patients who achieved complete remission following reduced intensity conditioning and
allogeneic stem cell transplantation. A nested-polymerase chain reaction with patient-spe-
cific primers derived from complementarity determining regions (CDR2 and CDR3) was
carried out in all the patients. Real-time polymerase chain reaction was performed in
patients whose nested reaction gave positive or mixed results.
Results
Three patterns of minimal residual disease were observed: negative (31%), mixed (24%),
and always positive (45%). The cumulative incidence of relapse according to the minimal
residual disease status at 6 and 12 months after transplantation was significantly different
between polymerase chain reaction-negative and -positive patients (p=0.031 and p=0.04,
respectively). Two-year disease-free survival was 93% and 46% for polymerase chain
reaction-negative and -positive patients at 6 months after transplantation, respectively
(p=0.012). Similarly, 2-year disease-free survival was 100% and 57% for polymerase chain
reaction-negative and -positive patients at 12 months, respectively (p=0.037). No clinical
or biological factors were predictive of the achievement of polymerase chain reaction neg-
ativity after allogeneic stem cell transplantation. Graft-versus-host disease was more fre-
quent in patients who did not relapse (p=0.04). Quantitative monitoring of minimal resid-
ual disease was able to identify polymerase chain reaction-positive patients with a higher
risk of relapse.
Conclusions
These findings demonstrate that relapsed patients can achieve molecular remission after
reduced intensity conditioning and allogeneic stem cell transplantation and suggest a min-
imal residual disease-driven intervention that might be useful to prevent overt hematolog-
ic relapse.
Key words: chronic lymphocytic leukemia; minimal residual disease; allogeneic stem cell
transplantation.
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Introduction 
Patients with relapsed chronic lymphocytic leukemia
(CLL) are candidates for intensive treatments to attain
remission and possibly prevent disease recurrence.
Autologous stem cell transplantation (SCT) may
improve patients’ outcome, although a continuous pat-
tern of relapse has been observed.1-3 At present, allo-
geneic SCT is considered a potentially curative treat-
ment since survival curves of allografted patients have
been observed to plateau.4-6 The main advantage provid-
ed by allografting may be the immune-mediated graft-
versus-leukemia effect.7,8 In the last decade an increasing
number of patients have been referred for an allogeneic
SCT with reduced intensity conditioning (RIC), which
has been shown to be feasible in patients over the age
of 55 years, in heavily pre-treated subjects and even in
those affected by other medical comorbidities.9-13
The availability of a molecular tumor marker, based
on the immunoglobulin heavy-chain gene (IgH)
rearrangement, allows post-transplant monitoring of
minimal residual disease (MRD) in patients in complete
remission. After autologous SCT, MRD negativity has
been correlated with a better disease-free survival.14-16 In
the allogeneic SCT setting, persistent MRD positivity
without relapse has been described by some authors
and has sometimes been used to modulate the post-
transplant immunosuppressive therapy in order to stim-
ulate anti-tumor activity.14-17
In the present study, we performed a prospective
molecular monitoring of patients with relapsed and
refractory CLL treated with RIC allogeneic SCT. Three
main issues were addressed: i) the rate of molecular
remissions; ii) the clinical relevance of MRD results; iii)
the clinical and biological factors, if any, that can be cor-
related with MRD status.
Design and Methods
Patients’ characteristics
Twenty-nine patients with relapsed CLL who
achieved complete remission after RIC allogeneic SCT
were monitored for MRD by a polymerase-chain-reac-
tion (PCR) assay. The patients’ characteristics and the
RIC regimens are described in Tables 1 and 2. Patients
were enrolled in three RIC allogeneic SCT Italian multi-
center protocols because they were primary refractory
to fludarabine-based regimens or had relapsed after two
or more lines of chemotherapy or after an autologous
SCT. The conditioning regimens consisted of thiotepa-
cyclophosphamide-fludarabine for recipients of trans-
plants from HLA identical siblings, thiotepa-cyclophos-
phamide- antithymocyte globulin for unrelated allo-
geneic SCT (n=6) and thiothepa-cyclophosphamide-flu-
darabine-alemtuzumab and 2 Gy total body irradiation
for haploidentical transplants (n=2).13,18,19 Graft-versus-
host disease (GVHD) prophylaxis was carried out with
a short-course of methotrexate and cyclosporine A in
the case of HLA-matched donors. Cyclosporine A was
tapered from day +100 in sibling transplants and from
day +180 in unrelated transplants. Early withdrawal of
immunosuppression followed by donor lymphocyte
infusions was allowed for persistent, progressive or
relapsed disease in patients without GVHD. The proto-
cols did not include a pre-established plan of donor lym-
phocyte infusions or withdrawal of immunosuppres-
sion based on the MRD results. GVHD was graded
according to consensus criteria.20,21 Chimerism was
assessed on peripheral blood as previously described.22
Molecular analyses were performed during the clini-
cal follow-up and patients gave their written informed
consent.
Molecular analysis
The IgH rearrangement was identified on diagnostic
bone marrow or peripheral blood samples using 500 ng
of genomic DNA extracted after mononuclear cell sepa-
ration on a Ficoll-Hypaque density gradient. PCR ampli-
fication was performed using four sets of consensus
sense primers derived from the IgH leader or frame-
work 1 (FR1) regions and an antisense primer derived
from the joining region (JH) at the 3’ end.23 Direct
sequencing of amplified DNA was performed using
automated sequencing. The IgH sequence was then
compared with the human germline sequences using
the Immunogenetics (IMGT) database (http://imgt.
cines.fr, IMGT, European Bioinformatics Institute,
Montepellier, France), the IGBLast search
(http://www.ncbi.nlm.nih.gov/igblast/, National Cancer for
Biotechnology Information, Bethesda, MD, USA), and
VBASE directory of DNAPLOT (http://vbase.mrc-
cpe.cam.ac.uk, Centre for Protein Engineering,
Cambridge, United Kingdom). IgH rearrangements
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Table 1. Patients’ characteristics.
Number 29
Median age, years (range) 60 (44-69)
Unmutated IgH (%) 22/29 (76)
17p deletion (%) 6/16 (38)
Median time from diagnosis to allogeneic SCT, months 46 (12-243)
Median n. of prior therapies (range) 3 (1-6)
Prior autologous SCT (%) 9 (31)
Disease status before transplant
Chemosensitive (%) 18 (62)
Complete remission 6
Partial remission 12
Chemorefractory (%) 11(38)
Donor type and RIC regimen/GVHD prophylaxis
HLA identical sibling (%) 21 (72)
Thio 10 mg/kg-Flu 60 mg/m2-Cy 60 mg/Kg / MTX-CSA
Unrelated (%) 6 (21)
Thio 10 mg/kg-Cy 100 mg/kg-ATG7.5 mg/Kg / MTX-CSA 
HLA haploidentical sibling (%) 2 (7)
Thio 10 mg/kg-Flu 120 mg/m2-Cy 60 mg/Kg-TBI 
200 cGy-CAM 15 mg/m2
IgH: immunoglobulin heavy-chain gene rearrangement; SCT: stem cell 
transplantation; RIC: reduced intensity conditioning; GVHD: graft-versus-host
disease.Thio: thiotepa; Flu: fludarabine; Cy: cyclophosphamide; MTX: methotrexate;
CSA: cyclosporine; ATG: antithymocyte globulin; CAM: alemtuzumab;TBI: total body
irradiation.
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Table 2. Pre-transplant characteristics of the patients’ and their outcome.
UPN M/F Age Time to VDJ FISH Auto S/R Disease Previous Donor Chim. CSA Acute Chronic PCR Clinical
alloSCT % SCT status therapies stop GVHD GVHD results outcom
9 M 49 12 98 na 0 S PR FC, DHAP id sibl FD (6m) 5m 2 (6m) Ext Neg Alive, CR 
26 F 69 96 90 tri12 0 R MR F, CHOP, FCR id sibl FD 15m 1 0 Neg Alive, C
(12m) (5m)
31 M 56 37 96 na 0 R MR FC id sibl FD no 1 (d50) Lim (6m) Neg Alive, CR 
142 M 64 121 100 na 0 R MR FCR, id sibl FD no 0 Ext (10m) Neg Alive, CR
Chl, EDX (12m)
178 M 49 13 100 del17p 0 S PR FC id sibl FD 10m 0 0 Neg Alive, CR
6 M 49 35 100 na 0 S PR Chl, F, DHAP, id sibl FD 9m 3 0 Neg Alive, CR 
FC (5m)
2U M 51 30 99 na 0 R PD F, FCR, RT MUD FD 12m 0 0 Neg Alive, CR 
3U M 61 80 99 na 0 R PD F, EDX, FC MUD FD 24m 2 (3m) Ext Neg Alive, CR
6U M 52 59 99 46 XY 1 S CR Chl, R-DHAP, MUD MC 7m 0 0 Neg Alive, CR
HDS, R-DHAP (12m)
11 F 55 30 99 na 0 S CR Chl, CVP, id sibl FD no 2 Ext Mix Alive, CR 
FC, CA (2m) (9m)
27 M 63 40 100 del13 0 R MR CHOP, FC, id sibl FD no 2 (2m) Ext Mix Alive, CR
36 M 54 17 100 del17p 0 R MR APO, FCR, id sibl FD 6m 1 0 Mix Dead, 
del13 DHAP, HypercHiddam, (d40) disease
tri12 CAM
37 M 58 15 100 del17p 0 S CR FC, DHAP, id sibl FD 6m 0 0 Mix Dead, TRM
Ara-c
30 F 51 34 100 tri12 0 S CR R-DHAP, FC, id sibl FD 34m 2 Ext Mix Alive, CR
Ara-c (5m)
34 M 60 243 96 46XY 0 S PR EDX, Chl, F, id sibl FD 16m 0 Lim (7m) Mix Alive, CR
Ara-c
50 M 60 98 96 compl 1 S PR Chl, F, FM, id sibl FD (3m) No 2 Ext Mix Alive, CR
ASCT, R-CHOP (d75)
16 M 60 25 99 na 0 S CR CHOP, R, FC, id sibl FD 9m 0 0 Pos Alive, 
DHAP (4m) relapsed
17 F 60 46 96 46XY 0 S CR F, FC, DHAP id sibl FD 9m 0 0 Pos Alive, 
relapsed
28 M 64 72 99 na 1 S PR Chl, F, DHAP, id sibl FD (6m) 4m 0 0 Pos Dead,
ASCT disease
29 F 60 159 100 na 1 S PR F, FC, DHAP, id sibl FD (3m) 19m 0 Ext (8m) Pos Dead,
ASCT disease
179 F 62 86 100 del13 0 S PR Chl, R-CHOP, id sibl FD 11m 0 0 Pos Dead, 
Ara-c disease
1U M 52 34 100 na 0 S PR CVP, FC, Chl, MUD MC 3m 0 0 Pos Alive, 
ASCT relapsed
4U M 44 73 99 na 1 S PR FC, Chl, R, F, MUD FD 12m 0 0 Pos Alive,
R-DHAP, ASCT relapsed
1A F 64 95 98 del17p 1 R PD EDX, CAM, aplo FD na 2 Ext Pos Dead, 
DHAP, ASCT (2m) TRM
2A M 62 39 100 del17p 1 R SD APO, DHAP, aplo FD (3m) na 2 Ext Pos Dead,
R-EDX, R-Ara-c, (d45) TRM
CAM, ASCT
33 M 62 12 99 na 0 R MR CHOP, FCR id sibl MC No 2 Ext Pos Alive, CR
(12m) (d45)
123 F 54 94 93 46XY 0 S PR Chl, FCR id sibl FD 10m 2 Lim Pos Alive,
(2m) (8m) relapsed
7U M 56 36 93 del17p 1 S PR Flu, CHOP, ASCT, MUD MC 8m 0 0 Pos Alive,
del13 FR, DHAP CR
111 M 64 84 100 46XY 1 R PD F, FM, EDX, id sib FD no 3 Ext Pos Alive, 
ASCT, DHAP, CAM (3m) CR
chim: chimerism; FC: fludarabine, cyclophosphamide; DHAP: dexamethasone,aracytin, cisplatin; F: fludarabine; CHOP: cyclophosphamide,adriamycin, vincristine,prednisone; FCR: flu-
darabine, cyclophosphamide, rituximab; Chl: chlorambucil; EDX: cyclophosphamide; RT: radiotherapy; R-DHAP: rituximab,dexamethasone,aracytin, cisplatin; HDS: high dose sequential
chemotherapy (HD-cyclophosphamide,HD-aracytin,BEAM); CVP: cyclophosphamide,vincristine,prednisone; CAM: alemtuzumab; APO: adriamycin, vincristine,prednisone;
HypercHiddam: methotrexate, cyclophosphamide,aracytin; FM: fludarabine,mitoxantrone; ASCT: autologous stem cell transplant (BEAM).Compl: complex karyotype.FD: full donor;
MC: mixed chimera; m: month; d: day; ext: extensive; lim: limited.When chronic GVHD was progressive after acute GVHD the date of onset is missing.No: ongoing immune suppressive
therapy.Na: not available/not applicable; S: sentivive; R: refractory.
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showing 98% or more homology to the closest match-
ing germline sequence were assigned as unmutated.24
After their allogeneic transplant, patients were moni-
tored from the time when complete remission was doc-
umented according to the NCI criteria.25 Serial post-
transplant bone marrow samples were analyzed by
nested-PCR, as previously described.23 Briefly, the first
PCR amplification was carried out with the consensus
primer derived from the tumor VH family and the anti-
sense primer derived from the 3’ end of the JH region.
The second reaction was performed using patient-spe-
cific primers constructed within the complementarity
determining regions CDR2 and CDR3. The PCR condi-
tions were established according to the melting tem-
perature of the primers. Five hundred nanograms of
DNA were used in the first PCR reaction, and 1 µL of
the PCR product was used for the second PCR.
Real-time PCR was performed using an ABI Prism
7700 Sequence Detection System® (Applied Bio-
systems, Foster City, CA, USA). Five hundred nano-
grams of DNA were amplified in 25 µL using 300 nm of
the individual patient-specific primers, 200 nm of
TaqMan probe and TaqMan Universal Mastermix
(Applied Byosistems, Foster City, CA, USA). A FR3-
derived consensus probe and the patient-specific
primers designed for the nested-PCR were used.26
Reaction conditions were established based on the
patients’ primers and probes. The glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) gene was chosen
as the reference standard. The relative quantification of
MRD was calculated as follows: ∆∆CT= (CTIgH
–CTGAPDH)follow-up – (CTIgH -CTGAPDH)pre-transplant.27 A mean CT
value was obtained by running experiments in tripli-
cate. In both qualitative and quantitative PCR reac-
tions: (i) a pre-transplant PCR-positive sample was used
as a positive control to assess the sensitivity; (ii) all the
samples were run in triplicate; (iii) a pool of DNA from
five healthy donors was used as a negative control in
order to assess the specificity; and (iv) a no-template
control sample was included to exclude any possible
contamination. To avoid false-negative results, all the
MRD-negative samples were tested by amplifying the
sequence of p53 exon 5 or exon 6.
Sensitivity tests were performed randomly in 20%
(n=6) of our patients, as part of the quality tests routine-
ly performed in the laboratory for MRD assessment. We
choose patients based on the availability of pre-trans-
plant samples in which the tumor cells approach 100%
of the cell content. Serial dilutions of CLL cells into a
pool of normal blood samples from five healthy donors
are performed in order to have samples with a tumor
content ranging from 100 to 10-7. Five hundred
nanograms of DNA of the samples are then used in real-
time PCR and nested-PCR carried out as described
above. A slope of the standard curves between -3.0 and
-3.9 and a correlation coefficient greater than 0.95 are
considered acceptable.28 The sensitivity ranges between
10-4 and 10-5 for real-time PCR, according to published
guidelines,29 and 10-6-10-7 for nested-PCR (Online
Supplementary Figure S1).
Statistical analysis
Molecular remission was defined as persistent PCR
negativity on serial bone marrow samples collected
after allogeneic SCT. Death from any cause and relapse
were considered as events for the analysis of disease-
free survival. Transplant-related mortality was defined
as death not related to progression of the malignant dis-
ease. The cumulative incidence of relapse was calculat-
ed using the cumulative incidence method, considering
relapse as an event and death without relapse as a com-
peting event. Two landmark time points were set at 6
and 12 months after transplantation.30-32 The cumula-
tive incidence of relapse of PCR-negative versus PCR-
positive patients at 6 or 12 months was compared by
Gray’s test.33 Disease-free survival rates were calculated
by the Kaplan-Meier method and compared with the
log-rank test. Patients who died or were censored
before the time of the landmark evaluation were
excluded from the analysis. Patients were analyzed and
compared from the landmark time to the last follow-up
according to MRD status at the landmark time regard-
less of any subsequent changes in MRD status.
Contingency tables were used to compare proportions
between groups.
Results 
Polymerase chain reaction results
In 29 out of 30 evaluated patients we were able to
identify the IgH-derived molecular marker.
A total of 148 samples from these 29 patients were
then analyzed for MRD, with the median time
between samples being 3 months (range, 1-30) (Figure
1). The overall median molecular follow-up of patients
alive and in complete remission was 26 months (range,
12-76) and the median clinical follow-up was 40
months (range, 12-85). At the last molecular follow-up
nine patients (31%) were PCR-negative: five of them
(17%) had always been PCR-negative, whereas the
other four (14%) experienced delayed clearance of
MRD within the first year after transplant. All these
patients were alive in complete remission with a medi-
an follow-up of 40 months (range, 15-85). Seven
patients (24%) showed a mixed pattern of alternating
PCR positivity and negativity: one patient died of sec-
ondary acute myeloid leukemia, another patient had a
nodal relapse (Richter’s syndrome) whereas the others
are alive and in complete remission. The median fol-
low-up of this group of patients was 46 months (range,
38-77). Thirteen patients (45%) were always PCR-pos-
itive: eight of them (28%) relapsed after a median of 9
months (range, 3-26). Two of the PCR-positive patients
(UPN 1a, 2a) died of extensive chronic GVHD after a
haploidentical transplant for 17p deletion refractory
CLL at 18 and 12 months respectively, whereas the
other three patients are alive and in complete remission
at a median follow-up of 49 months (range, 33-57).
Real-time PCR was carried out in six out of the 13
PCR-positive patients (Figure 2). In the remaining PCR-
positive patients quantitative monitoring was not per-
formed because of the small amount of DNA available.
Molecular remission in CLL
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In four patients (UPN 33, 1a, 2a, 7u) who did not
relapse, a decreasing (n=3) or stable (n=1) tumor load
was detected. The former were affected by extensive
chronic GVHD. In two more patients (UPN 17, 4u) the
tumor load increased on day +270 and +300 and both
patients relapsed without experiencing any GVHD. In
three out of the seven patients with a mixed PCR pat-
tern (UPN 11, UPN 27, UPN 37) we performed real-time
PCR, which gave negative results since we did not
observe any amplification in the follow-up samples. To
confirm the positivity by nested-PCR we sequenced the
PCR products which were 100% matched with the
DNA sequence of the diagnostic sample.
Four patients, who relapsed after allogeneic SCT,
were treated with chemo-immunotherapy followed by
donor lymphocyte infusions (DLI). UPN 16 developed
extensive chronic GVHD and attained a mixed PCR sta-
tus after chemotherapy and DLI: he is alive and in com-
plete remission 6 years after his transplant. UPN 17
received chemo-immunotherapy and DLI followed by
interferon-α: she achieved complete remission after
interferon-α, but never developed GVHD and relapsed
31 months later. UPN 123 showed a PCR-mixed status
lasting 34 months after rituximab and DLI followed by
limited GVHD. After having relapsed on day + 330,
UPN 4u received chemo-immunotherapy and DLI. He
did not develop GVHD and achieved molecular remis-
sion after DLI.
Clinical impact of polymerase chain reaction results
The relapse rate was significantly higher in PCR-pos-
itive patients than in PCR-negative patients and patients
with a mixed PCR pattern (p=0.003). The cumulative
incidence of relapse according to the MRD status at 6
months after allogeneic SCT was significantly different
between PCR-negative and PCR-positive patients
(p=0.031) (Figure 3B). The 2-year disease-free survival
was 93% and 46% for PCR-negative and PCR-positive
patients at 6 months after transplantation, respectively
(p=0.012) (Figure 3A). A second landmark analysis was
carried out at 12 months: the cumulative incidence of
relapse was 0% and 28% (p=0.040) and 2-year disease-
free survival was 100% and 57% for PCR-negative and
PCR-positive patients, respectively (p=0.037). 
Univariate analysis
In univariate analysis, chemorefractory status before
transplantation (p=0.702), the number of previous lines
of therapy (≤2 versus >2, p=0.451) and donor type
(HLA identical sibling versus matched unrelated/mis-
matched donors, p=0.225) were not significantly corre-
lated with the achievement of molecular remission.
Since most of the patients had an unmutated IgH, any
difference in MRD status between patients with mutat-
ed and unmutated IgH could not be detected. Three of
six patients carrying a 17p deletion achieved a PCR-
negative or mixed status (UPN 178, 36, 37), and one of
them relapsed with  Richter’s syndrome. Of the other
patients with 17p deletion, UPN 7u is alive, in PCR-
positive complete remission at 57 months after allo-
geneic SCT, whereas UPN 1a and 2a died of GVHD in
PCR-positive complete remission. We did not observe
any significant correlation between the achievement of
a rapid PCR-negativity and disease burden, assessed by
peripheral lymphocytosis, bone marrow lymphocyte
infiltration greater than  50% or the presence of bulky
lymph nodes (> 5 cm) and splenomegaly at the time of
transplantation. In particular, UPN 178 and 2U had
splenomegaly in association with a bone marrow infil-
trate greater than 50% and peripheral lymphocytosis,
Figure 1. Minimal residual disease monitoring by allele-specific oligonucleotide-nested-polymerase chain reaction. PCR: polymerase
chain reaction; TRM: transplant-related mortality; CT: chemotherapy; mAb: monoclonal antibody; DLI: donor lymphocyte infusion; CSA:
cyclosporine; GVHD: graft-versus-host disease. 
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As regard chimerism status, 69% of the patients who
were PCR-negative or had a mixed PCR pattern always
showed full donor reconstitution after their transplant
compared to 46% of PCR-positive patients (p=0.274). 
Seventy-five percent of PCR-negative/mixed patients
experienced GVHD compared to 46% of PCR-positive
patients (p=0.142). In PCR-negative patients with a
delayed clearance of MRD (UPN 26, 31, 6, 3u), the onset
of GVHD preceded the achievement of molecular
remission. In the PCR-positive group, GVHD occurred
in 25% of patients who relapsed and in 80% of those
who did not. Overall, the crude incidence of grade 2-4
acute and chronic GVHD was 22% and 70% in relapsed
and not relapsed patients, respectively (p=0.040).
Discussion
Molecular monitoring of MRD has been used in CLL
patients undergoing autologous or allogeneic transplan-
tation with rather different results. After autologous
SCT, it has been shown that PCR status correlates with
disease-free survival: PCR-positive patients and PCR-
Molecular remission in CLL
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Figure 2. Minimal residual disease monitoring by real-time polymerase chain reaction. MR: molecular remission; TRM: transplant-relat-
ed mortality; CR: complete remission; PD: progressive disease; aGVHD: acute graft-versus-host disease; cGVHD: chronic graft-versus-host
disease; DLI: donor lymphocyte infusion.
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negative patients becoming positive inevitably relapse.14-16
On the other hand, after conventional allogeneic SCT a
delayed clearance of MRD has been observed, suggest-
ing a role for the postulated graft-versus-leukemia
effect.14-16 Moreover, quantitative PCR monitoring
revealed three different kinetics of the tumor clone: sta-
ble and decreasing MRD levels were associated with
persistent complete remission, whereas increasing MRD
levels predicted relapse.16,17 Recently, data from a series
of 30 patients treated in the setting of a prospective RIC
allogeneic SCT protocol were reported by the German
CLL Study group.34 It was confirmed that post-transplant
immune therapy can induce molecular responses
through the graft-versus-leukemia effect, although some
patients may be or become resistant to such an effect
due to unknown mechanisms of immune escape. Along
with this study our series of PCR-monitored CLL
patients is the largest published so far concerning molec-
ular outcomes following RIC allogeneic SCT. The results
support the existence of different molecular disease pat-
terns and show that about one third of the patients can
achieve stable molecular remission. The lower rate of
molecular remission compared to those in other studies
may be explained by three observations: (i) the sensitiv-
ity of a nested-PCR with patient-specific primers can be
higher than that of real-time PCR or one-step PCR; (ii)
the assessment of MRD was performed on bone mar-
row rather than peripheral blood samples: although
recent guidelines for MRD detection have demonstrated
the correlation between bone marrow and peripheral
blood data, the authors did not exclude that results could
change in different settings;35 and (iii) in our group of
patients the rate of first or second remissions as well as
the number of matched unrelated donors were lower
(41% vs. 59% and 21% vs. 57%, respectively), whereas
more patients were chemorefractory at the time of
transplantation than in the series studied by the German
group (38% vs. 23%). 
Our MRD monitoring identified a group of patients
with a mixed PCR pattern who had a similar outcome to
that of the PCR-negative patients. We hypothesized that
these patients have a very low tumor burden that may
not always be detected by nested-PCR. The persistence
of a very low level of MRD could also explain the nega-
tive results found by real-time PCR that, at least in our
hands, is usually one-log less sensitive. To exclude the
occurrence of false positive results, PCR products of
patients with a mixed PCR pattern were randomly
sequenced showing a 100% match with the DNA
sequence of the positive control. The demonstration of
persistent low tumor burden in patients in long-term
complete remission could support the role of the graft-
versus-leukemia effect. In the clinical setting of prospec-
tive MRD monitoring, we suggest assigning the term
PCR-mixed at the time when a PCR-positive result is
obtained in previously PCR-negative patients. Although
real-time PCR was negative in our tested patients, in
these cases quantitative MRD monitoring might be use-
ful to exclude a rapid increase in tumor genomes. 
Interestingly, we sought to identify some factors, such
as donor type and previous treatment, which could pre-
dict the probability of achieving molecular remission,
but no significant associations were found. Besides the
limitation of the sample size, this result may suggest that
the graft-versus-leukemia effect provided by allogeneic
SCT may overcome the poor clinical prognostic factors.
Similarly, other authors have already shown the advan-
tage of an allogeneic SCT in patients with mutated as
well as unmutated IgH.6,17 As regards the presence of the
17p deletion, which is usually correlated with a poor
outcome, the fact that two patients (UPN 178, UPN 37)
achieved negative and mixed PCR results lasting 30
months is encouraging, as is the observation of an ongo-
ing complete remission at 3 years of follow-up in a PCR-
positive patient (UNP 7u). Moreover, since our patients
had unfavorable prognostic features the relatively long
disease control further supports the hypothesis that both
complete and molecular remissions are sustained by
Figure 3. Clinical impact of polymerase chain reaction results. (A) Disease-free survival from 6 months after RIC allogeneic SCT of PCR-
negative and PCR-positive patients based on MRD status at that time point (p=0.012). (B) Cumulative incidence of relapse of PCR-neg-
ative and PCR-positive patients based on MRD status at 6 months after RIC allogeneic SCT (p=0.031).
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mechanisms different from the cytotoxicity provided
by the conditioning regimen.
Donor-derived immune cells are potentially capable
of mediating an anti-tumor effect either specifically or
as a part of an alloreactive phenomenon. Thus, the
graft-versus-leukemia effect may be revealed by the
occurrence of GVHD, as demonstrated by the signifi-
cantly lower incidence of GVHD in relapsed patients
and by the occurrence of GVHD prior to achievement
of molecular remission in those displaying a delayed
clearance of MRD. The correlation between GVHD and
response has already been reported by other authors in
the context of MRD and in clinically detectable dis-
ease.34,36,37
It is of note that in our series the MRD status at 6
months was able to predict relapse, differently from the
report by Moreno et al. after conventional allogeneic
SCT.16 The difference was maintained even for the 12-
month landmark analysis, as reported by the German
group in the setting of RIC allogeneic SCT.34 Although
survival analysis based on MRD results must be consid-
ered with caution,30-32 disease-free survival rates from 6
and 12 months after RIC allogeneic SCT were better for
PCR-negative patients, based on PCR data at that time
point. Our data support the notion that rather early PCR
monitoring is able to predict the long-term outcome. In
particular, since the withdrawal of immunosuppression
in our patients usually started from day +100 and +180
in recipients of related and unrelated transplants, respec-
tively, the time point at 6 months could be particularly
useful for driving clinical decisions towards DLI admin-
istration in HLA-identical sibling transplants or faster
withdrawal of immunosuppression in the unrelated set-
ting, in the case of MRD positivity. Based on our results
and those of others, we can conclude that assessments
at 6 and 12 months are informative and should, there-
fore, be included in the post-transplant monitoring of
patients.
In summary, the evidence of three patterns of molec-
ular disease and their significant correlation with dis-
ease-free survival could lead to MRD-oriented interven-
tions: (i) PCR-negative patients are at a very low risk of
disease recurrence and they can have a slow decrease of
their immunosuppressive therapy, thus lowering their
risk of GVHD; (ii) patients with a mixed PCR pattern
had an outcome similar to that of PCR-negative
patients, but closer PCR monitoring is necessary
because of the persistence of a small clone, probably
controlled by the immune system, and quantitative
monitoring may be advisable when positive results
occur; we can speculate that altogether, PCR-negative
patients and patients with a mixed PCR pattern repre-
sent most of the 50-60% of progression-free survivors
reported in many phase II RIC allogeneic SCT trials in
CLL;9-13 and (iii) PCR-positive patients are at high risk of
overt relapse and withdrawal of their immunosuppres-
sive therapy followed by therapeutic intervention may
be encouraged. Quantitative PCR monitoring is strong-
ly indicated in this setting to assess the timing and type
of intervention. The fact that some PCR-positive
patients do not relapse or can be rescued after DLI fur-
ther supports the role of the graft-versus-leukemia effect
and the development of pre-emptive approaches based
on molecular results.
In conclusion, our data indicate that molecular moni-
toring should be incorporated into clinical studies
employing allogeneic SCT in CLL patients in order to
further confirm these results and to generate robust
MRD-based guidelines for post-transplant management
of the patients.
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